Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Eli Lilly stock undercut its 50-day line on Jan. 14 after cutting its fourth-quarter and 2024 outlook. Is LLY stock a sell ...

AbbVie's CEO hinted his company may be less willing to invest in psychiatry after a costly setback, while Lilly explained ...

Wockhardt’s experimental drug, Zaynich, has shown impressive results, achieving a 100% cure rate in clinical trials for ...

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between ...

Fourth-quarter earnings at JPMorgan Chase, Wells Fargo, Goldman Sachs, and Citigroup beat analysts’ estimates.

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.